Cover Image
市場調查報告書

全球基因治療市場預測

Global Gene Therapy Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 312362
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
Back to Top
全球基因治療市場預測 Global Gene Therapy Market Outlook 2020
出版日期: 2015年09月01日 內容資訊: 英文 155 Pages
簡介

全球基因治療產業,到2020年末隱藏著數百萬美元規模產業的可能性。

本報告提供全球基因治療市場相關調查分析、產業的趨勢與推動要素、阻礙因素、市場預測、法規形勢,包含主要企業分析等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 基因治療:簡介

  • 基因治療技術的分類
  • 基因轉移的物理性手法
  • 基因治療用媒介

第4章 產業概要

  • 推動市場要素
    • 對於癌症治療的傳支配療的失敗
    • 已開發國家的基因治療藥產品化的加速
    • 關乎生命的慢性病的增加
    • 風險企業投資公司的關注高漲
  • 阻礙市場要素
    • 嚴格法規與安全性相關疑慮
    • 目前技術中的陷阱
    • 治療成本高
  • 市場機會
    • 歐洲已批准基因治療藥
    • B型血友病的基因治療上有大機會到來
  • 產業趨勢
    • 基因抑制:達成躍進
    • 先進的治療:組合基因治療與幹細胞技術
    • 免疫不全症候群:基因治療的中心
    • 奈米技術:基因治療活性化
    • 基因治療:給失明治療光明
    • 基因治療:癌症治療的潛力
  • 成功的規範

第5章 臨床試驗評估及開發平台分析

  • 臨床試驗評估
    • 各地區
    • 各適應症
    • 各遺傳基因類型
    • 各媒介
    • 各臨床試驗階段
  • 開發平台分析

第6章 基因治療市場:法規形勢及醫療費償付情形

  • 法規形勢
    • 美國
    • 加拿大
    • 歐洲
    • 日本
    • 中國
    • 印度
    • 澳洲

第7章 市售的基因治療藥

  • Neovasculgen
  • Glybera
  • Gendicine, Rexin-G, Oncorine

第8章 全球基因治療市場

第9章 各用途基因治療市場

  • 腫瘤
  • 循環系統疾病
  • 感染疾病
  • 神經疾病
  • 遺傳性疾病
  • 其他

第10章 全球基因治療市場規模:各地區

  • 北美
  • 歐洲
  • 亞洲
  • 其他地區

第11章 競爭情形

  • 各企業僱用的策略
    • 策略性合作
    • 收購
    • 資金籌措、投資
  • 以基因治療飛躍的企業

第12章 主要企業分析(營業內容、臨床實驗平台、最新趨勢、優勢和弱點等)

  • Spark Therapeutics, LLC
  • ViroMed Co. Ltd. dba VM BioPharma
  • Advantagene Inc
  • Bluebird Bio
  • Sanofi
  • Vical Inc
  • Oxford BioMedica Plc
  • Genethon
  • UniQure N.V.
  • Human Stem Cells Institute
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Gene therapy is a therapeutic technique which replaces damaged proteins in the cell by artificially introducing the DNA into a cell. Majority of the metabolic or genetic disorders are a consequence of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or erase the genes causing a particular disease is the basis of gene therapy. Despite the fact that gene therapy has not contributed fundamentally to the global pharmaceutical market yet, it is expected to grow at a fast pace over the next decade.

As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

According to RNCOS' new research report "Global Gene Therapy Market Outlook 2020", a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc.

The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and 'difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

  • 3.1 Classification of Gene Therapy Techniques
  • 3.2 Physical Methods of Gene Transfer
    • 3.2.1 Electroporation
    • 3.2.2 Hydrodynamic
    • 3.2.3 Microinjection
    • 3.2.4 Particle Bombardment
    • 3.2.5 Ultrasound-Mediated Transfection
  • 3.3 Vectors for Gene Therapy
    • 3.3.1 Viral Vectors
      • 3.3.1.1 Adenoviral Vectors
      • 3.3.1.2 Adeno-associated Virus Vectors
      • 3.3.1.3 Retroviral Vectors
      • 3.3.1.4 Lentiviral Vectors
    • 3.3.2 Non Viral Vectors
      • 3.3.2.1 Naked DNA/Plasmid Vectors
      • 3.3.2.2 Oligonucleotides
      • 3.3.2.3 Liposomes, Lipoplexes and Polyplexes
      • 3.3.2.4 Gene-Activated Matrix

4. Industry Overview

  • 4.1 Market Drivers
    • 4.1.1 Failure of Conventional Therapies to Treat Cancers
    • 4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
    • 4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
    • 4.1.4 Growing Interest of Venture Capital Firms
  • 4.2 Market Restraints
    • 4.2.1 Stringent Regulatory Laws & Safety Concerns
    • 4.2.2 Pitfalls in Current Technique
    • 4.2.3 High Cost of the Gene Therapy Drugs
  • 4.3 Market Opportunities
    • 4.3.1 Approval of Gene Therapy Drug in Europe
    • 4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
  • 4.4 Industry Trends
    • 4.4.1 Gene Silencing: Gaining Momentum
    • 4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
    • 4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
    • 4.4.4 Nanotechnology: Empowering Gene Therapy
    • 4.4.5 Gene Therapy: A New Hope to Treat Blindness
    • 4.4.6 Gene Therapy: Potential Cure for Cancer
  • 4.5 Winning Imperatives
    • 4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis

  • 5.1 Clinical Trials
    • 5.1.1 By Geography
    • 5.1.2 By Indication
    • 5.1.3 By Gene Type
    • 5.1.4 By Vector
    • 5.1.5 By Clinical Trial Phase
  • 5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

  • 6.1 Regulatory Landscape
    • 6.1.1 US
    • 6.1.2 Canada
    • 6.1.3 Europe
    • 6.1.4 Japan
    • 6.1.5 China
    • 6.1.6 India
    • 6.1.7 Australia
  • 6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies

  • 7.1 Neovasculgen
  • 7.2 Glybera
  • 7.3 Gendicine, Rexin-G, Oncorine
    • 7.3.1 Gendicine
    • 7.3.2 Rexin G
    • 7.3.3 Oncorine

8. Global Gene Therapy Market

9. Gene Therapy Market by Application

  • 9.1 Oncology
  • 9.2 Cardiovascular Diseases
  • 9.3 Infectious Diseases
  • 9.4 Neurological Diseases
  • 9.5 Genetic Diseases
  • 9.6 Others

10. Global Gene Therapy Market Size by Geography

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia
  • 10.4 Rest of the World (RoW)

11. Competitive Landscape

  • 11.1 Strategies Adopted by Various Players
    • 11.1.1 Strategic Collaborations
    • 11.1.2 Acquisitions
    • 11.1.3 Funding & Investments
  • 11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)

  • 12.1 Spark Therapeutics, LLC
  • 12.2 ViroMed Co. Ltd. dba VM BioPharma
  • 12.3 Advantagene Inc.
  • 12.4 Bluebird Bio
  • 12.5 Sanofi
  • 12.6 Vical Inc.
  • 12.7 Oxford BioMedica Plc
  • 12.8 Genethon
  • 12.9 UniQure N.V.
  • 12.10 Human Stem Cells Institute
  • 12.11 Shanghai Sunway Biotech Co. Ltd.
  • 12.12 Sibiono GeneTech Co. Ltd.

List of Figures:

  • Figure 4-1: Global - Venture Capitalist Investments in Gene Threapy Product Development (Billion US$), 1999 to H1 2015
  • Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
  • Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents till July, 2015
  • Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries till July, 2015
  • Figure 5-4: Global - Gene Therapy Clinical Trials by Indication till July, 2015
  • Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred till July, 2015
  • Figure 5-6: Global - Gene Therapy Clinical Trials by Percentage of Vectors Used till July, 2015
  • Figure 5-7: Global - Gene Therapy Clinical Trials by Phase till July, 2015
  • Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
  • Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
  • Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
  • Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
  • Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
  • Figure 9-3: Global - Gene Therapy Oncology Market (Million US$), 2014, 2015 & 2020
  • Figure 9-4: Global - Gene Therapy Oncology Market by Geography (%), 2015
  • Figure 9-5: Global - Gene Therapy Cardiovascular Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-6: Global - Gene Therapy Cardiovascular Disease Market by Geography (%), 2015
  • Figure 9-7: Global - Gene Therapy Infectious Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-8: Global - Gene Therapy Infectious Disease Market by Geography (%), 2015
  • Figure 9-9: Global - Gene Therapy Neurological Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-10: Global - Gene Therapy Neurological Disease Market by Geography (%), 2015
  • Figure 9-11: Global - Gene Therapy Genetic Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-12: Global - Gene Therapy Genetic Disease Market, by Geography (%), 2015
  • Figure 9-13: Global - Gene Therapy Other Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-14: Global - Gene Therapy Other Disease Market by Geography (%), 2015
  • Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
  • Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
  • Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
  • Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
  • Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
  • Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
  • Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
  • Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

  • Table 4-1: US - Gene Therapies under Development
  • Table 4-2: Europe - Gene Therapies under Development
  • Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
  • Table 4-4: Current Status of Clinical Trials for Hemophilia
  • Table 5-1: Human Gene Transfer Trials Approved by Condition till 2012
  • Table 5-2: Key Ongoing Gene Therapy Clinical Trials
  • Table 6-1: China - Key Players and their Products in Gene Therapy
  • Table 9-1: Vectors Used for Cardiovascular Gene Transfer
  • Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
  • Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
  • Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
  • Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
  • Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
  • Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
  • Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
  • Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
Back to Top